DeCure for Amyloidosis, primary localized cutaneous, 1
DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for amyloidosis, primary localized cutaneous, 1 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAmyloidosis, primary localized cutaneous, 1 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for amyloidosis, primary localized cutaneous, 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A long-term follow-up of 7% progression to systemic disease was observed in nodular localised primary cutaneous amyloidosis, based on cases seen at one dermatology institute between 1968 and 1999. This is far lower than the 50% rate previously quoted in the literature. A separate case report described a patient with extensive nodular cutaneous amyloidosis who had no systemic involvement or paraproteinaemia after six years of follow-up.
A study from northern India enrolled 62 patients with suspected cutaneous amyloidosis, of whom 38 were confirmed histopathologically. Of these, 63% had macular amyloidosis, and the interscapular area was the most common site (53%). The study reported that pruritus, pigmentation, and papules responded excellently to topical dimethylsulphoxide after one month of treatment. The authors concluded that dimethylsulphoxide seemed effective, but the abstract provides no response rates, no control group, and no longer-term follow-up data.
A review article notes that cutaneous amyloidosis and skin changes from systemic amyloidosis are diagnosed more often in Southeast Asia, China, and South America than in Europe. It states that treatment remains disappointing overall.
What is still missing: randomised controlled trials for dimethylsulphoxide, long-term outcome data beyond one month, validated patient stratification by amyloid subtype, and dedicated funding for a disease that is rare in Western populations.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Dermatology · 2001 · 161 citations
Nodular localized primary cutaneous amyloidosis: a long-term follow-up study
AbstractWe present long-term follow-up data on patients with nodular localized primary cutaneous amyloidosis (NLPCA) seen at the St John's Institute of Dermatology between 1968 and 1999. This is the largest clinical follow-up study of this type of amyloid to date. Based on these cases we estimate the rate of progression of NLPCA to systemic amyloidosis to be only 7%, much lower than the 50% rate currently quoted in the literature.
Indian Dermatology Online Journal · 2012 · 26 citations · open access
Study on epidemiology of cutaneous amyloidosis in northern India and effectiveness of dimethylsulphoxide in cutaneous amyloidosis
AbstractCONTEXT: Amyloidosis, which is characterized by the extracellular deposition of a proteinaceous substance, is usually associated with considerable tissue dysfunction. However, the etiology of the disease remains uncertain and the treatment disappointing. AIM: 1. To know the epidemiology of cutaneous amyloidosis 2. To evaluate the effect of dimethylsulphoxide on cutaneous amyloidosis. SETTINGS AND DESIGN: Data was collected from patients attending the Outpatient Department (OPD) over a period of one year. MATERIAL AND METHODS: Patients were screened on the basis of signs and symptoms and then confirmed histologically. A total of 62 patients who were suspected to be suffering from amyloidosis on the basis of clinical signs and symptoms and 38 patients who were further confirmed histopathologically underwent the treatment. STATISTICAL ANALYSIS USED: Chi-square test was used for testing the significance of proportions. RESULTS: 63.15 percent of the patients had macular amyloidosis and the interscapular area was the most common area involved (52.63%). Pruritus, pigmentation, and papules responded excellently to dimethylsulphoxide after one month of treatment. CONCLUSIONS: Cutaneous amyloidosis is a disease found in middle-aged persons, with a female preponderance, and dimethylsulphoxide seems to be an effective therapy.
AbstractNodular cutaneous amyloidosis (NCA), the least common form of primary cutaneous amyloidosis, is characterized clinically by waxy, purpuric plaques and nodules and histologically by amyloid deposits in the dermis and subcutaneous tissue. We present a patient who developed multiple, non-contiguous NCA lesions over a three year period without evidence of systemic disease. We reviewed the literature and found few other cases of this unusual presentation.
Journal of the European Academy of Dermatology and Venereology · 2005 · 11 citations
Extensive nodular cutaneous amyloidosis: an unusual presentation
AbstractAmyloidosis is characterized by the deposition of a group of unrelated proteins leading to changes in tissue architecture and function. The nodular variant is the rarest form of the cutaneous amyloidoses. We report a patient with localized nodular amyloidosis without systemic amyloid involvement or paraproteinaemia after 6 years of follow-up. The unusual aspects of our case were a plaque presentation rather than nodular, and the disseminated pattern observed.
Journal of Cosmetic and Laser Therapy · 2017 · 2 citations
Successful treatment of primary cutaneous localized amyloidosis with a combined therapy of ablative fractionated CO<sub>2</sub> laser, topical retinoid, corticosteroids and levovitamin C: Five cases with two-year follow-up
AbstractPrimary cutaneous localized amyloidosis (PCLA) is a pruritic disorder with no radical cure. We trialed a combined therapy of ablative fractionated CO2 laser, topical retinoid, corticosteroids and levovitamin C on five patients. All patients responded with no intolerant signs. Two-year follow-up visit showed no recurrence. This might be a effective method awaiting more samples for further stronger evidence.
AbstractThe symptoms of amyloidosis depend directly on the localization of amyloid deposits: it can be accumulated in only one body organ (localized amyloidosis) or in more than one organ system (systemic amyloidosis). The possibility of skin lesions exists in both cases. Cutaneous amyloidosis and skin changes induced by systemic amyloidosis are diagnosed significantly more often in Southeast Asia, China and South America than in Europe. The aim of this article was to review the forms of cutaneous amyloidosis, the main skin changes induced by systemic amyloidosis, symptoms, diagnosis and methods of treatment. Despite of the big diversity of the symptoms, some of them could be very important in the diagnosis of both localized cutaneous and systemic amyloidosis. The review of the newest publications of cutaneous amyloidosis, the comprehensive classification, symptoms and the main principles of diagnosis and treatment are presented.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
